人民财讯1月8日电，广州市人民政府办公厅印发《广州市加快建设先进制造业强市规划(2024—2035 年)》。其中提出，加速创新药物战略布局，大力发展单克隆抗体、疫苗、血液制品、诊断试剂等生物 制药。围绕生命健康重大问题和前沿生物技术开展前瞻布局，争取在基因工程技术、新的药物靶点和作 用机制、合成生物学与生物信息学融合等方面取得突破。借助岭南中药特色优势，加快推动中医药标准 化、国际化，打造一批从原料药、中药材到药品的示范产业链。 ...

（原标题：阿尔及利亚将成为"非洲的药房"） 《曙光报》12月21日报道，阿尔及利亚药学联合会主办的第九届全国药学大会于12月21日至23日召 开，会议围绕多个重要议题展开讨论，包括精准医疗、创新药物、罕见病治疗，以及数字化和人工智能 在药品追溯中的应用。阿尔及利亚药学联合会主席布迪斯·阿卜杜勒哈基姆表示，鉴于阿尔及利亚各制 药实验室生产的药品在数量、质量和技术水平方面不断提升，阿尔及利亚很快将成为"非洲的药房"。他 指出，目前本国药品生产已满足82%的国内需求，因此大会讨论的重点之一为开拓阿尔及利亚以外的药 品市场及出口便利化问题。 联合会秘书长穆罕默德·亚辛·阿舒里则指出，阿尔及利亚药学领域近年来登记了多种创新药物，但 部分药品价格偏高，会议就此进行讨论。他补充说，罕见病及其患者的诊疗保障已成为联合会近期重要 关注，同时还重点关注慢性疾病（尤其是糖尿病和高血压）治疗药物的评估问题。 ...

【环球网财经综合报道】日前，国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药 品目录》以及《商业健康保险创新药品目录》，自2026年1月1日起正式执行。这是国家医保局成立以来第8次调整医 保药品目录。本次医保药品目录调整新增114种药品，其中50种为1类创新药。 值得关注的是，本次调整后，多款罕见病药物被纳入2025年医保目录及商保创新药目录。其中复星医药的芦沃美替尼 片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新药目录。同时，5款CAR-T药进入商保创新药目 录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的 伊基奥仑赛注射液、科济药业的泽沃基奥仑赛注射液。 国家医疗保障局党组书记、局长章轲还表示，将加快基于医保数据、医保立项和支付的场景，加快医保影像云建设， 力争2027年以前基本实现医保影像的全国互通互认。 《南华早报》近日发文称，花旗银行亚太区医疗保健研究总监约翰·杨表示，"未来几年，生物科技，尤其是创新药 物，肯定会是中国的头等大事。"他认为，中国需要通过升级生产线和生产能力，以及扩大临床管理能力，来发展 ...

Core Viewpoint - Daiwa Capital Markets maintains a "Buy" rating for Alibaba Health with a target price of HKD 7.8, highlighting strong financial performance exceeding expectations [1] Financial Performance - For the first half of the fiscal year 2026, Alibaba Health reported a revenue increase of 17% year-on-year and an adjusted net profit increase of 38.7%, surpassing both the firm's and market expectations [1] - The company reiterated its fiscal year 2026 targets, aiming for revenue growth of 10-15% and adjusted net profit growth of 20-30% [1] Future Growth Projections - Daiwa forecasts a compound annual growth rate (CAGR) for revenue and adjusted net profit of 13% and 24%, respectively, for the fiscal years 2026-2028, driven by ongoing growth in innovative drugs and health products, deeper synergies with the Alibaba ecosystem, and expanding AI applications [1]

Group 1 - The core viewpoint of the article highlights the establishment of a commercial insurance innovative drug directory in medical insurance negotiations, aimed at addressing the accessibility and affordability of high-priced innovative drugs, particularly for rare disease treatments and high-value innovative medications [1] - The introduction of a "dual directory" negotiation method allows pharmaceutical companies to adopt more flexible application strategies [1] - Domestic innovative drugs are becoming significant competitors to imported drugs in areas such as bispecific antibodies and antibody-drug conjugates (ADC) [1] Group 2 - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets to reflect the overall performance of biopharmaceutical-related listed companies [1]

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for global companies to showcase their innovations and engage with key decision-makers in the Chinese pharmaceutical market [1][2][3] - Gilead Sciences has experienced the benefits of the CIIE, particularly in accelerating the approval and market entry of innovative therapies in China [1][2][3] Policy and Regulatory Environment - China's continuous policy reforms in drug approval processes have created a favorable environment for innovative drugs, enhancing the attractiveness of the Chinese market for multinational pharmaceutical companies [1][2] - The establishment of expedited approval channels for breakthrough therapies and conditional approvals has significantly reduced the time for innovative drugs to enter the Chinese market [2][3] Market Dynamics and Opportunities - The CIIE has become a "policy windfall" and "information hub" for new drugs entering China, allowing companies to effectively communicate with regulatory bodies and enhance product recognition among healthcare professionals and patients [2][3] - Gilead's innovative drugs, such as Lenacapavir and Seladelpar, have demonstrated rapid approval and market entry following their showcases at the CIIE, highlighting the event's role in expediting access to new treatments [3][4][7] Collaboration and Local Partnerships - Gilead is actively pursuing collaborations with local pharmaceutical companies and healthcare platforms to strengthen its supply chain and enhance product accessibility in China [9][10] - The company is also focusing on educational initiatives to reduce stigma around diseases like HIV, thereby fostering a more informed patient population and improving market conditions [9][10] Future Directions - Gilead plans to continue its focus on both treatment and prevention in the HIV space, exploring innovative dosing regimens to improve patient adherence [8][9] - The company is engaged in multiple clinical studies globally, with a significant emphasis on advancing HIV treatment and prevention strategies [8][11] - Gilead's ongoing partnerships and collaborations with local innovators reflect a broader trend of multinational companies seeking to capitalize on China's growing pharmaceutical market [12]

Core Viewpoint - China Resources Pharmaceutical announced the establishment of a 500 million yuan fund focused on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane (600062) and China Resources Pharmaceutical Investment as limited partners [1] - China Resources Pharmaceutical Group plans to invest 123 million yuan, accounting for approximately 24.6% of the total fund size [1] - Shenzhen China Resources Capital will act as the fund manager [1] Group 2: Strategic Goals - The establishment of the fund aligns with the group's strategic direction in synthetic biology, aiming to build an industrialization platform in Hohhot [1] - The fund is expected to enhance investment channels, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - Once established, the fund will be recorded as equity investment in the company's consolidated financial statements [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced the establishment of a proposed fund with a scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1 - The fund will be established through a limited partnership agreement involving China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners [1] - The total commitment from the group will be RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1]

Core Insights - Eli Lilly's stock has shown significant performance, with a 5.02% increase on September 30, marking a cumulative rise of 6.77% over three days, driven by political support, drug approvals, and market competition [1][2] Group 1: Drug Approvals and Market Impact - Eli Lilly's new Alzheimer's drug, Kisunla (donanemab), received EU market approval, enhancing its global market presence after approvals in Australia, the US, Japan, and China [1] - Kisunla targets amyloid plaques in the brain, potentially becoming an innovative therapy for Alzheimer's, with studies indicating it effectively slows cognitive and functional decline [1] - The drug's limited treatment regimen alleviates economic and medical burdens on patients, offering a new approach to healthcare systems [1] Group 2: Competitive Position in Oncology - Eli Lilly's oral selective estrogen receptor degrader, Inluriyo, has been approved by the FDA for specific breast cancer patients, showing significant advantages over traditional endocrine therapies [2] - Inluriyo is designed for estrogen receptor-positive, HER2-negative, ESR1 mutation breast cancer patients, reducing the risk of disease progression or death [2] - The company aims to enhance its competitiveness in breast cancer treatment through combination therapies and precision medicine, establishing a stronger foundation for market competition [2]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the Chinese stock market, which is valued at $19 trillion and has recently regained interest from foreign investors after being deemed uninvestable three years ago [1][4]. Core Insights and Arguments - **Market Recovery**: The Shanghai Composite Index reached a ten-year high, and the Hong Kong stock market hit a four-year high, driven by improved market sentiment due to the US-China tariff truce and a loose domestic monetary environment [4][6]. - **Foreign Investment Trends**: There is a notable shift in foreign investor sentiment, with hedge funds purchasing Chinese stocks in August, marking the highest trading volume in six months [4][5]. - **Diversification Interest**: Investors are seeking diversification away from crowded US assets, with some planning to establish platforms to facilitate US and European capital entry into the Chinese market [4][5]. - **Emerging Market Funds**: The number of newly established emerging market funds (excluding China) is projected to decline significantly, indicating a cooling demand for investments in these markets [4][5]. - **Reevaluation of China**: China is increasingly viewed as a standalone asset class, with significant interest from global investors, contrasting with previous sentiments that sought to exclude China from indices [5][6]. Additional Important Insights - **Investment Consultations**: There has been a marked increase in inquiries about Chinese funds, with about 30 clients consulting investment firms this year, compared to very few in 2023 [6]. - **Economic Concerns**: Despite the positive sentiment, China's economy remains fragile, with industrial output and retail sales data indicating ongoing weakness. Foreign direct investment fell by 13.2% in the first five months of 2025 compared to the previous year [6][7]. - **Long-term Outlook**: Investors are in a "re-rating" phase, assessing China's long-term competitiveness, but many remain cautious and have not yet committed significant capital [7]. Conclusion - The Chinese stock market is experiencing a resurgence in foreign interest, driven by technological advancements and a desire for diversification. However, underlying economic challenges persist, necessitating careful consideration by potential investors.